Safety and efficacy of the neo-modified cabrol procedure with cabrol-fistula in 469 patients with low coronary ostia aortic root aneurysm

Abstract

Objectives

The study objectives were to evaluate the clinical efficacy, safety, and applicability of the neo-modified Cabrol procedure.

Methods

This study uses a retrospective cohort design of 469 patients who underwent the neo-modified Cabrol procedure between December 2012 and June 2023. Cross-sectional follow-up was performed between September 2023 and February 2024. The fate of the coronary interposition graft was evaluated by reviewing the data and images from computed tomography angiography of the aorta and coronary arteries of the follow-up patients.

Results

A total of 469 patients (mean age 53.7 ± 10.7 years; 409 male and 60 female patients) were included. The mean follow-up was 3.14 years (range, 0.00-9.95 years) for a total of 1472.84 patient-years. All-cause mortality rate within 30 days was 2.6% (n = 12). Outpatient/telephone/WeChat follow-up was completed by 100% of discharged patients (n = 457). Actuarial survivals were 95.9% ± 0.1%, 89.4% ± 0.2%, and 78.1% ± 0.6% at 1, 5, and 10 years, respectively. There were no neo-modified Cabrol procedure interposition graft–related complications, such as coronary fistula, pseudoaneurysm, graft twisting, stenosis, occlusion, or thrombosis.

Conclusions

The neo-modified Cabrol procedure is a safe and effective approach, offering favorable perioperative outcomes and long-term graft patency. Multicenter randomized controlled trials are needed to comprehensively evaluate the effectiveness of this technique.